Vandetanib could inhibit tumour cell proliferation and survival by blocking EGFR and could inhibit tumour-induced neo-angiogenesis by blocking VEGF activity and has been investigated in a variety of human cancers, including NSCLC (Wedge et al, 2001; Wilhelm et al, 2004; Naumov et al, 2009; Morabito et al, 2010). Here, EGFR is linked to cancer.